Groupama Asset Managment Has $274.12 Million Holdings in Insulet Co. (NASDAQ:PODD)

Groupama Asset Managment trimmed its holdings in shares of Insulet Co. (NASDAQ:PODD) by 0.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,050,000 shares of the medical instruments supplier’s stock after selling 517 shares during the period. Insulet makes up 2.0% of Groupama Asset Managment’s investment portfolio, making the stock its 13th largest holding. Groupama Asset Managment’s holdings in Insulet were worth $274,124,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. SBI Securities Co. Ltd. acquired a new stake in Insulet in the fourth quarter worth $36,000. SRS Capital Advisors Inc. boosted its position in shares of Insulet by 43.1% during the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock worth $49,000 after purchasing an additional 56 shares in the last quarter. TD Private Client Wealth LLC grew its stake in shares of Insulet by 32.6% in the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after buying an additional 56 shares during the period. Friedenthal Financial bought a new stake in Insulet in the 4th quarter valued at about $57,000. Finally, Assetmark Inc. grew its stake in Insulet by 1,447.1% in the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier’s stock valued at $69,000 after acquiring an additional 246 shares during the period.

Insider Buying and Selling at Insulet

In other Insulet news, Director Wayne A.I. Frederick sold 1,825 shares of the company’s stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the transaction, the director now directly owns 3,231 shares in the company, valued at $888,525. This represents a 36.10 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

Wall Street Analysts Forecast Growth

PODD has been the topic of a number of research reports. Canaccord Genuity Group upped their target price on Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Citigroup boosted their target price on Insulet from $310.00 to $355.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Raymond James reissued an “outperform” rating and issued a $328.00 price objective (up previously from $294.00) on shares of Insulet in a research report on Friday, February 21st. Royal Bank of Canada assumed coverage on Insulet in a research report on Thursday, March 6th. They set an “outperform” rating and a $340.00 target price for the company. Finally, Wells Fargo & Company boosted their price target on shares of Insulet from $305.00 to $322.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. Four equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $292.06.

Insulet Trading Up 1.5 %

Shares of PODD stock opened at $262.61 on Tuesday. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $289.46. The company’s fifty day simple moving average is $271.42 and its two-hundred day simple moving average is $259.20. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The stock has a market capitalization of $18.44 billion, a price-to-earnings ratio of 45.36, a PEG ratio of 3.62 and a beta of 1.29.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.15. The company had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. As a group, analysts anticipate that Insulet Co. will post 3.92 earnings per share for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.